.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Chubb
Medtronic
Johnson and Johnson
Teva
QuintilesIMS
Chinese Patent Office
Queensland Health
Mallinckrodt
Citi

Generated: September 23, 2017

DrugPatentWatch Database Preview

TAZORAC Drug Profile

« Back to Dashboard

What is the patent landscape for Tazorac, and when can generic versions of Tazorac launch?

Tazorac is a drug marketed by Allergan and is included in two NDAs.

The generic ingredient in TAZORAC is tazarotene. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the tazarotene profile page.

Summary for Tradename: TAZORAC

Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list3
Bulk Api Vendors: see list85
Clinical Trials: see list17
Patent Applications: see list4,673
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TAZORAC at DailyMed

Pharmacology for Tradename: TAZORAC

Ingredient-typeRetinoids
Drug ClassRetinoid
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600-001Jun 13, 1997RXYesYes► Subscribe► Subscribe► Subscribe
Allergan
TAZORAC
tazarotene
CREAM;TOPICAL021184-002Sep 29, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600-002Jun 13, 1997RXYesYes► Subscribe► Subscribe► Subscribe
Allergan
TAZORAC
tazarotene
CREAM;TOPICAL021184-001Sep 29, 2000RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TAZORAC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600-001Jun 13, 1997► Subscribe► Subscribe
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600-002Jun 13, 1997► Subscribe► Subscribe
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600-002Jun 13, 1997► Subscribe► Subscribe
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600-001Jun 13, 1997► Subscribe► Subscribe
Allergan
TAZORAC
tazarotene
CREAM;TOPICAL021184-002Sep 29, 2000► Subscribe► Subscribe
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600-001Jun 13, 1997► Subscribe► Subscribe
Allergan
TAZORAC
tazarotene
CREAM;TOPICAL021184-001Sep 29, 2000► Subscribe► Subscribe
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600-002Jun 13, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Teva
Novartis
Moodys
Baxter
Cantor Fitzgerald
US Department of Justice
Chinese Patent Office
Federal Trade Commission
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot